Northstrive Biosciences announced that it has scheduled a pre-Investigational New Drug, IND, meeting with the U.S. Food and Drug Administration ...

Northstrive Biosciences Inc. plans a pre-IND meeting with FDA to discuss EL-22 for muscle preservation in obesity treatments. Northstrive Biosciences Inc. has announced a pre-Investigational New ...

(“iTolerance”), a U.S. based regenerative medicine company, announced today the result from the Type B pre-IND meeting held by Kadimastem and iTolerance with a committee of the U.S Food and ...

Kadimastem Ltd. and Itolerance Inc. have held a type B pre-IND meeting with the FDA regarding the development of ITOL-102, an investigational biologic for the treatment and potential cure of type 1 ...

has announced a scheduled pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) set for April 23, 2025. The meeting will focus on the development of EL-22 ...

TAIPEI, Feb. 26, 2025 /PRNewswire/ -- Asia Scientific Global (ASG), a company specializing in the research and development of novel inhaled novel drugs, announced the completion of pre-IND meeting ...

26, 2025 /PRNewswire/ -- Asia Scientific Global (ASG), a company specializing in the research and development of novel inhaled novel drugs, announced the completion of pre-IND meeting with the U.S ...

Kadimastem and iTolerance believe that the completion of the pre-IND meeting is a significant milestone toward the clinical development of iTOL-102, an on-going collaborative research initiative ...